ClinicalTrials.gg
CompletedNCT01143038Updated Sep 21, 2022Results posted

Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim

A Phase 2 interventional study of Romiplostim in Idiopathic Thrombocytopenic Purpura, sponsored by Amgen. Completed at 48 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-21.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 6 under way, 2 of them phase 3. romiplostim · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
12th of 29
75 · median 62
Started
2010
the only one that year
Phase 2
8 of 29
1 open now
Registered
13th of 29
by date
Lead sponsor
14 of 29
Amgen

Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, this one is the 12th largest by enrollment, is the only one that started in 2010, is one of 8 in phase 2, and was the 13th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About romiplostim

romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

The purpose of this study is to describe the number of months with a platelet response over a 12 month treatment period and to describe ITP remission rates in adults with ITP receiving romiplostim.

Read the detailed description

The study includes a 4-week screening period, a 12-month romiplostim treatment period, and a romiplostim dose-tapering period.

During the 12-month treatment period romiplostim doses could be increased or decreased to maintain a platelet count between ≥ 50 x 10\^9/L and ≤ 200 x 10\^9/L. Participants who dose reduce such that they no longer require treatment with romiplostim during the 12-month treatment period will continue with all required study procedures up to 12 months and will be monitored for ITP remission for at least 6 months.

At the completion of the 12-month treatment period, participants receiving only romiplostim and with a platelet count ≥ 50 x 10\^9/L will enter the tapering period, during which the romiplostim dose will be decreased by 1 µg/kg every 2 weeks, for up to 19 weeks. If a participant maintains a platelet count of ≥ 50 x 10\^9/L in the absence of romiplostim and all medications for ITP (concomitant or rescue), the participant will be followed for at least 6 months to confirm the incidence of ITP remission. If a participant's platelet count falls below 50 x 10\^9/L and the participant has tapered off treatment with romiplostim, the participant will enter the stabilization period and reinitiate romiplostim for up to 8 weeks.

03

Conditions studied

  • Idiopathic Thrombocytopenic Purpura

Keywords

  • ITP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has been diagnosed with primary ITP according to the American Society of Hematology (ASH) guidelines (George et al, 1996) and previously received only therapies.

First line therapy is defined as , immunoglobulin G (IVIG), anti-D and vinca alkaloids (used for the treatment of ITP related thrombocytopenia only). A transfusion at any time during the six month period since the original diagnosis would not exclude the subject from study participation

  • Initial diagnosis of primary ITP within 6 months of enrollment
  • Age ≥ 18 years at screening
  • A single platelet count ≤ 30 x 10⁹/L at any time during the screening period
  • Subject or subject's legally acceptable representative has provided

Exclusion criteria

Exclusion Criteria:

  • Known history of a bone marrow stem cell disorder
  • Surgical resection of the spleen
  • Subject has a history of cancer or current other than basal cell carcinoma or cervical cancer in-situ with active treatment or disease within 5 years of screening
  • Known history of congenital thrombocytopenia
  • Known history of , , or
  • Positive H. pylori by urea breath test or stool antigen test at screening
  • Known history of systemic lupus erythematosus, Evans syndrome, or neutropenia
  • Known history of antiphospholipid antibody syndrome or positive for lupus anticoagulant
  • Known history of disseminated intravascular coagulation, hemolytic uremic syndrome, or thrombotic thrombocytopenic purpura
  • Previous history of recurrent venous thromboembolism or thrombotic events or an occurrence within 5 years of enrollment.
  • Previous use of romiplostim, pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), eltrombopag, recombinant human thrombopoietin (rHuTPO) or any producing agent
  • Rituximab (for any indication) or mercaptopurine (6-MP) or anticipated use during the time of the proposed study
  • All hematopoietic growth factors including interleukin-11 (IL-11) (oprelvekin) within 4 weeks before the screening visit
  • Alkylating agents use at any time before or during the screening visit or anticipated during the time of the proposed study
  • Known to any recombinant E. coli-derived product (eg, Infergen, Neupogen, Somatropin, and Actimmune)
  • Currently enrolled in another device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational agent(s)
  • Subject will have any other investigational procedures performed while enrolled in this clinical study
  • Subject is pregnant or breast feeding, or planning to become pregnant within 5 weeks after the end of treatment
  • Female subject of child bearing potential is not willing to use, in combination with her partner, highly effective during treatment and for 4 weeks after the end of treatment
  • Subject has previously enrolled into a romiplostim study
  • Subject will not be available for protocol required study visits, to the best of the subject's and investigator's knowledge
  • Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written and/or to comply with all required study procedures
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Romiplostim

    Participants received romiplostim administered weekly by subcutaneous injection during the 12-month treatment period. The starting dose was 1 μg/kg with weekly dose increases continued in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\^9/L.

    Biological: Romiplostim

Interventions

  • BiologicalRomiplostim

    Romiplostim will be administered weekly by subcutaneous injection

    Also known as: AMG 531, Nplate

06

What researchers measure

Primary outcomes

  1. Number of Months With Platelet Response During the 12-Month Treatment Period

    The primary endpoint was the number of months a participant achieved a platelet response during the 12-month treatment period. A platelet response for any 1 month was defined as the median of platelet counts measured in the month ≥ 50 x 10\^9/L. Platelet counts within 4 weeks following a rescue medication use or following splenectomy were considered non-response. Months without any platelet count measurement were considered as months with no platelet response.

    Time frame: 12 months

Secondary outcomes

  1. Percentage of Participants With ITP Remission

    ITP remission was defined as maintaining every platelet count ≥ 50 x 10\^9/L for at least 6 months in the absence of romiplostim and any other therapies to treat ITP.

    Time frame: Up to 24 months

  2. Percentage of Participants With Splenectomy During the 12-month Treatment Period

    If treatment with romiplostim was deemed ineffective or intolerable by the investigator, a splenectomy may have been performed.

    Time frame: 12 months

  3. Number of Participants With Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. The event does not necessarily have a causal relationship with study treatment. A serious adverse event is defined as an adverse event that meets at least one of the following serious criteria: • fatal • life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • congenital anomaly/birth defect • other significant medical hazard. Whether an adverse event was treatment-related (TRAE) or not was determined by investigator.

    Time frame: From first dose date of romiplostim to end of study (up to 24 months).

  4. Number of Participants Who Developed Antibodies to Romiplostim

    The number of participants who developed antibody formation (defined as negative at baseline and positive at post-baseline, transient or persistent) to romiplostim, endogenous thrombopoietin (eTPO), and thrombopoietin mimetic peptide (TMP, the peptide component of romiplostim) was summarized.

    Time frame: Baseline and at end of treatment (based on response to treatment, this could occur between 12 months and approximately 18 months)

07

Results

Posted Feb 24, 2016

Participant flow

Ninety-eight adults with immune thrombocytopenia purpura (ITP) were screened for the study; 23 were considered screen failures. Seventy-five participants were enrolled at 32 study centers in Australia, the European Union, and North America from 30 November 2010 to 21 September 2012.

Participant flow — Overall Study
MilestoneRomiplostim
Started75
Completed59
Not completed16
Withdrew: Withdrawal by subject4
Withdrew: Requirement for alternative therapy5
Withdrew: Adverse event3
Withdrew: Lost to follow-up2
Withdrew: Protocol deviation1
Withdrew: Death1

Outcome measures

PrimaryNumber of Months With Platelet Response During the 12-Month Treatment Period

The primary endpoint was the number of months a participant achieved a platelet response during the 12-month treatment period. A platelet response for any 1 month was defined as the median of platelet counts measured in the month ≥ 50 x 10\^9/L. Platelet counts within 4 weeks following a rescue medication use or following splenectomy were considered non-response. Months without any platelet count measurement were considered as months with no platelet response.

Time frame:
12 months
Reported as:
Mean · months
Number of Months With Platelet Response During the 12-Month Treatment Period
monthsRomiplostim
Number of Months With Platelet Response During the 12-Month Treatment Period9.2 ± 0.4
Statistical analysis
  • Romiplostim · Mean: 9.2 · 95% CI 8.3 to 10.1Based on the t-distribution
  • Romiplostim · Bootstrap mean: 9.1 · 95% CI 8.3 to 10.0Estimates are based on bootstrap method with 1000 samples with replacement.
SecondaryPercentage of Participants With ITP Remission

ITP remission was defined as maintaining every platelet count ≥ 50 x 10\^9/L for at least 6 months in the absence of romiplostim and any other therapies to treat ITP.

Time frame:
Up to 24 months
Reported as:
Number · percentage of participants
Percentage of Participants With ITP Remission
percentage of participantsRomiplostim
Percentage of Participants With ITP Remission32.0 (21.7 to 43.8)
SecondaryPercentage of Participants With Splenectomy During the 12-month Treatment Period

If treatment with romiplostim was deemed ineffective or intolerable by the investigator, a splenectomy may have been performed.

Time frame:
12 months
Reported as:
Number · percentage of participants
Percentage of Participants With Splenectomy During the 12-month Treatment Period
percentage of participantsRomiplostim
Percentage of Participants With Splenectomy During the 12-month Treatment Period1.3 (0.0 to 7.2)
SecondaryNumber of Participants With Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. The event does not necessarily have a causal relationship with study treatment. A serious adverse event is defined as an adverse event that meets at least one of the following serious criteria: • fatal • life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • congenital anomaly/birth defect • other significant medical hazard. Whether an adverse event was treatment-related (TRAE) or not was determined by investigator.

Time frame:
From first dose date of romiplostim to end of study (up to 24 months).
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsRomiplostim
All adverse events63
Serious adverse events17
Leading to discontinuation of romiplostim4
Leading to discontinuation from study3
Fatal adverse events0
Treatment-related adverse event21
Treatment-related serious adverse events3
TRAE leading to discontinuation of romiplostim2
TRAE leading to discontinuation from study2
Treatment-related fatal adverse events0
SecondaryNumber of Participants Who Developed Antibodies to Romiplostim

The number of participants who developed antibody formation (defined as negative at baseline and positive at post-baseline, transient or persistent) to romiplostim, endogenous thrombopoietin (eTPO), and thrombopoietin mimetic peptide (TMP, the peptide component of romiplostim) was summarized.

Time frame:
Baseline and at end of treatment (based on response to treatment, this could occur between 12 months and approximately 18 months)
Reported as:
Number · participants
Number of Participants Who Developed Antibodies to Romiplostim
participantsRomiplostim
Antibodies to romiplostim2
Antibodies to TPO1
Antibodies to TMP2
Neutralizing antibodies to romiplostim1
Neutralizing antibodies to TPO0
Neutralizing antibodies to TMP0

Adverse events

Collected over From first dose date of romiplostim to end of study (up to 24 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Romiplostim—17/75 (22.7%)50/75 (66.7%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventRomiplostim
Idiopathic Thrombocytopenic PurpuraBlood and lymphatic system disorders1/75
ThrombocytopeniaBlood and lymphatic system disorders1/75
Atrial FibrillationCardiac disorders1/75
HypothyroidismEndocrine disorders1/75
Abdominal PainGastrointestinal disorders1/75
FaecalomaGastrointestinal disorders1/75
GastritisGastrointestinal disorders1/75
ErysipelasInfections and infestations1/75
Tendon RuptureInjury, poisoning and procedural complications1/75
Transaminases IncreasedInvestigations1/75
Most frequent other events
Showing 10 of 20
Most frequent other events
EventRomiplostim
HeadacheNervous system disorders13/75
ArthralgiaMusculoskeletal and connective tissue disorders11/75
NasopharyngitisInfections and infestations10/75
HaematomaVascular disorders8/75
InfluenzaInfections and infestations7/75
CoughRespiratory, thoracic and mediastinal disorders7/75
PetechiaeSkin and subcutaneous tissue disorders7/75
FatigueGeneral disorders6/75
Upper Respiratory Tract InfectionInfections and infestations6/75
EpistaxisRespiratory, thoracic and mediastinal disorders6/75

Baseline characteristics

Age, Continuous
Age, Continuous(years)Romiplostim
Mean44.5 ± 18.7
Sex: Female, Male
Sex: Female, Male(Participants)Romiplostim
Female44
Male31
Race
Race(participants)Romiplostim
American Indian or Alaska Native0
Asian1
Black (or African American)1
Native Hawaiian or Other Pacific Islander0
White72
Other0
Unknown1
Ethnicity
Ethnicity(participants)Romiplostim
Hispanic/Latino6
Not Hispanic/Latino69
Time since ITP diagnosis
Time since ITP diagnosis(months)Romiplostim
Median2.2 (0.1 to 6.6)
Platelet Count at Screening
Platelet Count at Screening(x 10^9/L)Romiplostim
Mean19.78 ± 15.80
08

Study locations

48 sites
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Boynton Beach, Florida 33435, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Research Site
    Hickory, North Carolina 28602, United States
  • Research Site
    Philadelphia, Pennsylvania 19140, United States
  • Research Site
    Charleston, South Carolina 29414, United States
  • Research Site
    Richlands, Virginia 24641, United States
  • Research Site
    Randwick, New South Wales 2031, Australia
  • Research Site
    Woolloongabba, Queensland 4102, Australia
  • Research Site
    Adelaide, South Australia 5000, Australia
  • Research Site
    Brno, 625 00, Czechia
  • Research Site
    Ostrava-Poruba, 708 52, Czechia
  • Research Site
    Praha 10, 100 34, Czechia
  • Research Site
    Praha 2, 128 08, Czechia
  • Research Site
    Praha 2, 128 20, Czechia
  • Research Site
    Bondy Cedex, 93143, France
  • Research Site
    Créteil Cedex, 94010, France
  • Research Site
    Dijon, 21000, France
  • Research Site
    Pessac Cedex, 33604, France
  • Research Site
    Toulouse Cedex 9, 31059, France
  • Research Site
    Dresden, 01307, Germany
  • Research Site
    Duisburg, 47166, Germany
  • Research Site
    Düsseldorf, 40479, Germany
  • Research Site
    Köln, 50674, Germany
  • Research Site
    Bari, 70124, Italy
  • Research Site
    Catania, 95124, Italy
  • Research Site
    Monza (MB), 20900, Italy
  • Research Site
    Napoli, 80131, Italy
  • Research Site
    Novara, 28100, Italy
  • Research Site
    Roma, 00161, Italy
  • Research Site
    San Giovanni Rotondo FG, 71013, Italy
  • Research Site
    Vicenza, 36100, Italy
  • Research Site
    Gdansk, 80-952, Poland
  • Research Site
    Katowice, 40-032, Poland
  • Research Site
    Lublin, 20-080, Poland
  • Research Site
    Poznan, 61-505, Poland
  • Research Site
    Wroclaw, 50-367, Poland
  • Research Site
    Málaga, Andalucía 29010, Spain
  • Research Site
    Barcelona, Cataluña 08035, Spain
  • Research Site
    A Coruña, Galicia 15006, Spain
  • Research Site
    Alcorcon, Madrid 28922, Spain
  • Research Site
    Majadahonda, Madrid 28222, Spain
  • Research Site
    Coventry, CV2 2DX, United Kingdom
  • Research Site
    Leeds, LS9 7TF, United Kingdom
  • Research Site
    London, E1 2ES, United Kingdom
  • Research Site
    London, SW17 0QT, United Kingdom
  • Research Site
    Oxford, OX3 9DU, United Kingdom
09

References and documents

Publications

  • Newland A, Godeau B, Priego V, Viallard JF, Lopez Fernandez MF, Orejudos A, Eisen M. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. Br J Haematol. 2016 Jan;172(2):262-73. doi: 10.1111/bjh.13827. Epub 2015 Nov 5. PubMed 26537623 ↗
  • Cines DB, Wasser J, Rodeghiero F, Chong BH, Steurer M, Provan D, Lyons R, Garcia-Chavez J, Carpenter N, Wang X, Eisen M. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica. 2017 Aug;102(8):1342-1351. doi: 10.3324/haematol.2016.161968. Epub 2017 Apr 14. PubMed 28411254 ↗
  • Kuter DJ, Newland A, Chong BH, Rodeghiero F, Romero MT, Pabinger I, Chen Y, Wang K, Mehta B, Eisen M. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. Br J Haematol. 2019 May;185(3):503-513. doi: 10.1111/bjh.15803. Epub 2019 Feb 21. PubMed 30793285 ↗
  • Kuter DJ, Arnold DM, Rodeghiero F, Janssens A, Selleslag D, Bird R, Newland A, Mayer J, Wang K, Olie R. Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials. Am J Hematol. 2020 Jun;95(6):643-651. doi: 10.1002/ajh.25776. Epub 2020 Mar 21. PubMed 32129511 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2010 to primary completion in Sep 2013, 33 months.

Results were first posted in Feb 2016, 2 years 5 months after primary completion. A results delay was requested in May 2014.

Of 66 phase 2 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 33 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2010
First posted
Jun 14, 2010
StartActual
Nov 30, 2010
Primary completionActual
Sep 20, 2013
CompletionActual
Dec 26, 2013
Results delay requested
May 29, 2014
Results first posted
Feb 24, 2016
Last update
Sep 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01143038
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jun 14, 2010
Start date
Nov 30, 2010
Primary completion
Sep 20, 2013
Completion
Dec 26, 2013
Results posted
Feb 24, 2016
Last update
Sep 21, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion